FIELD: immunology, biotechnology. SUBSTANCE: vaccine has a polynucleotide containing human gene encoding papilloma virus (HPV) taken among the group consisting of HPV 6a, HPV 6b, HPV 11, HPV 16 and HPV 18 and expressing protein L1 or L1 + L2, promoter CMV, terminator of transcription from bovine gene encoding growth hormone, gene-marker determining the resistance to neomycin and physiologically acceptable solution. Invention provides immune protective effect against infection with papilloma virus. EFFECT: enhanced effectiveness of vaccine. 4 cl, 7 dwg, 7 ex
Title | Year | Author | Number |
---|---|---|---|
PAPILLOMA VIRUS PURIFIED PROTEINS | 1995 |
|
RU2161651C2 |
PAPILLOMA VIRAL VACCINES | 1995 |
|
RU2206608C2 |
EXPRESSING VECTOR (VARIANTS) | 1995 |
|
RU2177999C2 |
DNA STRUCTURE (VARIANTS), DNA-VECTOR, IMMUNOGENIC COMPOSITION AGAINST INFLUENZA VIRUS, METHOD OF IMMUNE RESPONSE INDUCTION, VACCINE AND METHOD OF VACCINATION | 1994 |
|
RU2193065C2 |
OPTIMISED EXPRESSION OF HPV 58 L1 IN YEAST | 2004 |
|
RU2370538C2 |
OPTIMISED EXPRESSION LI HPV45 IN YEAST | 2004 |
|
RU2360001C2 |
NUCLEIC ACID MOLECULE ENCODING HPV 31 L1, EXPRESSION VECTOR, HOST CELL, VIRUS-LIKE PARTICLE AND METHOD OF ITS OBTAINMENT, VACCINE, PHARMACEUTICAL COMPOSITION AND METHODS INVOLVING THEM | 2004 |
|
RU2356943C2 |
OPTIMISED EXPRESSION OF HPV 52 L1 IN YEAST | 2005 |
|
RU2373219C2 |
POLYNUCLEOTIDE ANTITUBERCULOSIS VACCINE | 1995 |
|
RU2186109C2 |
VACCINE COMPOSITION APPLICABLE IN HPV AND HEPATITIS VIRUS INFECTIONS, AND METHOD FOR PREPARING IT | 2009 |
|
RU2509570C2 |
Authors
Dates
2001-09-10—Published
1995-06-01—Filed